Leading the way to safer medication
 Crosscheck  Recommender

Pioglitazone

Description

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

ATC Classification

Code
Title
Category
A10BG03
Pioglitazone
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BG Thiazolidinediones

Trade names

Trade name
Countries

Australia

Australia

Australia Austria Netherlands Singapore Spain

Austria

Austria

Austria

Australia

Trade names (in combination): ACTOPLUS MET COMPETACT DUETACT GLUBRAVA INCRESYNC OSENI TANDEMACT

Product Monographs

Monograph
Type
Country
ACTOS Tablet
MPI, US: SPL/PLR
US
PIOGLITAZONE ACCORD Tablet
MPI, EU: SmPC
UK